BRUSSELS, April 14 (KUNA) – The European Medicines Agency (EMA) introduced Wednesday that its security committee is reviewing very uncommon instances of surprising blood clots that occurred within the United States following the usage of Janssen’s COVID-19 vaccine. US health and illness management our bodies beneficial yesterday that the usage of the vaccine ought to be paused whereas they evaluate six reported instances within the United States. More than 6.8 million doses of the vaccine have been administered, mentioned the EMA based mostly in Amsterdam in a press launch.
Janssen has introduced their resolution to delay the rollout of the vaccine within the EU whereas investigations proceed. The vaccine was licensed within the EU on 11 March 2021 however widespread use of the vaccine inside the EU has not but began.
EMA mentioned it’s investigating all of the instances reported and can determine whether or not regulatory motion is important.
While its evaluate is ongoing, EMA mentioned it stays of the view that the advantages of the vaccine in stopping COVID-19 outweigh the dangers of negative effects. COVID-19 Vaccine Janssen is a vaccine for stopping coronavirus illness 2019 (COVID-19) in folks aged 18 years and older. The commonest negative effects with COVID-19 Vaccine Janssen are normally gentle or reasonable and get higher inside one or two days after vaccination, it famous.
The put up EU company investigating studies on blood clots from use of Janssen vaccine appeared first on ARAB TIMES – KUWAIT NEWS.